Featured Research

from universities, journals, and other organizations

Research demonstrating link between virus and MS could point the way to treatment and prevention

Date:
January 9, 2012
Source:
Queen Mary, University of London
Summary:
A new study from researchers at Queen Mary, University of London shows how a particular virus tricks the immune system into triggering inflammation and nerve cell damage in the brain, which is known to cause MS.

A new study from researchers at Queen Mary, University of London shows how a particular virus tricks the immune system into triggering inflammation and nerve cell damage in the brain, which is known to cause MS.

Previous research has suggested a link between the Epstein-Barr virus (EBV) and multiple sclerosis but the research has remained controversial since scientists have so far failed to substantiate the link.

The new study proves the virus is involved in a manner more sophisticated and subtle than previously imagined, and may offer new ways to treat or prevent the disease.

MS is a neurological condition that affects around 100,000 people in the UK. It can cause vision problems, difficulties with walking and fatigue, and tends to strike mainly young and middle-aged women.

Its causes are not completely understood but both genes and environment are known to play a role.

Some previous research has suggested that EBV triggers MS but subsequent studies have failed to find the connection.

The new research, which is published in the journal Neurology, looked at post mortem brains of MS patients, examining areas where neurological damage had recently occurred.

Dr Ute-Christiane Meier from Barts and the London Medical School, part of Queen Mary, led the research. She explained: "EBV is quite a clever virus; when it's not growing and spreading it can hide away in our immune cells.

"In this study we used a different technique which allowed us to detect the virus in the brains of some people affected by MS, even when it was hiding away in the cells."

Dr Meier and her team of collaborators found that, although the virus was not actively spreading, it was releasing a chemical message into areas of the brain nearby. This chemical message -- made up of small RNA molecules -- was activating the body's immune system, causing inflammation. This damages nerve cells in the brain and causes MS symptoms.

Dr Meier continued: "We have to be careful and have to study more MS brains but this is potentially very exciting research. Now we understand how EBV gets smuggled into the brain by cells of the immune system and that it is found at the crime scene, right where the attack on our nervous system occurs. Now we know this, we may have a number of new ways of treating or even preventing the disease."

One possibility is the widely-used cancer treatment Rituximab; a drug which is known to kill the cells of the immune system in which the virus hides. It is now being trialed as a treatment for MS.

Another possible approach, using anti-viral treatment, will be tested in clinical trials currently in preparation by Professor Gavin Giovannoni and colleagues, also at Queen Mary.

"If we can pinpoint EBV as a trigger, it's possible that we could alter the course of MS or potentially even prevent the condition by treating the virus," Dr Meier added.

"MS so often strikes young women and its unpredictable nature makes it an incredibly difficult disease to live with. We desperately need better ways to tackle the condition."

Interestingly, the research also hinted that infection with EBV and its action on the immune system could also be playing a role in other brain diseases such as cancer and stroke.

This research was supported by the Medical Research Council and MS charities, Roan Charitable Trust and Aims2Cure.


Story Source:

The above story is based on materials provided by Queen Mary, University of London. Note: Materials may be edited for content and length.


Journal Reference:

  1. J. S. Tzartos, G. Khan, A. Vossenkamper, M. Cruz-Sadaba, S. Lonardi, E. Sefia, A. Meager, A. Elia, J. M. Middeldorp, M. Clemens, P. J. Farrell, G. Giovannoni, U.- C. Meier. Association of innate immune activation with latent Epstein-Barr virus in active MS lesions. Neurology, 2011; 78 (1): 15 DOI: 10.1212/WNL.0b013e31823ed057

Cite This Page:

Queen Mary, University of London. "Research demonstrating link between virus and MS could point the way to treatment and prevention." ScienceDaily. ScienceDaily, 9 January 2012. <www.sciencedaily.com/releases/2012/01/120105112042.htm>.
Queen Mary, University of London. (2012, January 9). Research demonstrating link between virus and MS could point the way to treatment and prevention. ScienceDaily. Retrieved July 23, 2014 from www.sciencedaily.com/releases/2012/01/120105112042.htm
Queen Mary, University of London. "Research demonstrating link between virus and MS could point the way to treatment and prevention." ScienceDaily. www.sciencedaily.com/releases/2012/01/120105112042.htm (accessed July 23, 2014).

Share This




More Health & Medicine News

Wednesday, July 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins